Dr. Thomas Szasz, Psychiatrist Who Led Movement Against His Field, Dies at 92 New York Times by BENEDICT CAREY September 11, 2012 Thomas Szasz, a psychiatrist whose 1961 book “The Myth of Mental Illness” questioned the legitimacy of his field and provided the intellectual grounding for generations of critics, patient advocates and antipsychiatry activists, making […]
Don’t do the crime, if you can’t do the time Sometimes, one gets to pass along something that matters on a blog. This article below matters. If you’re a reader here, you’re probably a person who could’ve written it [but maybe not gotten it into the NEJM]. I’ll bet you’ve certainly thought what it says […]
"None of the 10 measures relying on patient reported or parent reported outcomes showed significant advantage for an antidepressant, so that claims for effectiveness were based entirely on ratings by doctors." Efficacy and safety of antidepressants for children and adolescents by Jureidini, Doecke, Mansfield, Haby, Menkes, and Tonkin British Medical Journal. 2004 328:879-883. It’s ragweed […]
Becky commented about the publications from the American Academy of Child and Adolescent Psychiatry below. If you haven’t read them, please do. The first one is from 2004/2005: Do antidepressants increase the risk of suicide? Suicidal thoughts and behaviors are more common during adolescence than at any other time, but suicide is more common among […]
In the last post, I compared several graphs from the same study [X065 Lilly]. If, however, you look over the whole report for study X065, the graphs and the tables don’t match. My point is not to debunk the article. I can’t really do that because there are so many conflicting sources of information on […]
Change of plans. In the last episode… [as they said in the serials at the Saturday movies when I was a kid in the 40’s], I said I was going to show real raw data, then an example of how the summary data like in ClinicalTrials.gov might miss something important. I was going to use […]
In the last post [eyes wide shut open I…], I left off with the results from this study[An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain]. I’m not going to attempt to summarize all that’s posted [it’s easily accessed with 1-click here]. But here’s a sample, the posting […]
This is the abstract for a clinical trial from this month’s American Journal of Psychiatry. It’s not posted here to either praise or debunk. It’s just the most recent Clinical Trial I could find to illustrate another point [although it is kind of an interesting study]: A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate […]
I’m running out of titles – all quiet on the western front, the sounds of silence, the silent treatment – ways to describe the status of the DSM-5 Revision. There’s suddenly nothing to say. The full report on the field trials has yet to appear. The PR site, DSM-5 Facts, won’t even come up right […]
J&J Deal With The States ‘Is Huge’: Friede Explains Pharmalot By Ed Silverman September 6th, 2012 Late last month, Johnson & Johnson’s Janssen subsidiary agreed to pay $181 million to resolve claims by 36 states and the District of Columbia for promoting the Risperdal and Invega antipsychotic drugs for unapproved uses [see here]. The settlement […]